Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p5
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 5/16)
Character Range: 131338–134216

0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;
 except for smoking or burning.
DELPHINIUM STAPHISAGRIA except in preparations containing 0.2% or less of Delphinium staphisagria.
DESLORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when:
 (a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and
 (b) labelled with a recommended daily dose not exceeding 5 mg of desloratadine.
DEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:
 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 (b) in a day‑night pack containing dexchlorphenamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
 except in preparations for the treatment of children under 2 years of age.
DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.
DIBROMOPROPAMIDINE for ophthalmic use.
DICLOFENAC when:
 (a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac; or
 (b) in preparations for dermal use containing 4% or less of diclofenac except in preparations for dermal use containing 2% or less of diclofenac or for the treatment of solar keratosis; or
 (c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.
DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
DIPHENHYDRAMINE in oral preparations:
 (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
 (b) when combined with one or more other therapeutically active substances when:

          (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

          (ii) in a day‑night pack containing diphenhydramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
 except in preparations for the treatment of children under 2 years of age.
DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:
 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 (b) in a day‑night pack containing doxylamine in the bed‑time dose where